Gibas KM, Kelly SG, Arribas JR, Cahn P, Orkin C, Daar ES, et al. Two-drug regimens for HIV treatment. Lancet HIV. 2022; 9(12):e868-e883.
DOI: 10.1016/S2352-3018(22)00249-1
Cheney L, Barbaro JM, Berman JW. Antiretroviral Drugs Impact Autophagy with Toxic Outcomes. Cells. 2021; 10(4):909.
DOI: 10.3390/cells10040909
Smith SJ, Zhao XZ, Passos DO, Lyumkis D, Burke TR Jr, Hughes SH. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs. Viruses. 2021; 13(2):205.
DOI: 10.3390/v13020205
Kolakowska A, Maresca AF, Collins IJ, Cailhol J. Update on Adverse Effects of HIV Integrase Inhibitors. Curr Treat Options Infect Dis. 2019; 11(4):372-387.
DOI: 10.1007/s40506-019-00203-7
Richetta C, Tu NQ, Delelis O. Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance. Viruses. 2022; 14(12):2591.
DOI: 10.3390/v14122591
Podany AT, Scarsi KK, Pham MM, Fletcher CV. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review. Clin Pharmacokinet. 2020; 59(9):1085-1107.
DOI: 10.1007/s40262-020-00898-8
Mahajan PS, Burke TR Jr. Synthetic Approaches to a Key Pyridone-carboxylic Acid Precursor Common to the HIV-1 Integrase Strand Transfer Inhibitors Dolutegravir, Bictegravir, and Cabotegravir. Org Process Res Dev. 2023; 27(5):847-853.
DOI: 10.1021/acs.oprd.3c00063
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2023. Avalaible from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf [Accessed on August 11, 2024].
EACS Guidelines V12.0 2024. Available in: https://www.eacsociety.org/guidelines/eacs-guidelines/ [Accessed on August 11, 2024].
Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003; 32(1):48-56.
DOI: 10.1097/00126334-200301010-00007
Lagathu C, Béréziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf. 2019; 18(9):829-840.
DOI: 10.1080/14740338.2019.1644317
Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, García-Puig J, Moreno JA. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc Health Risk Manag. 2015; 11:35-48.
Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005; 19(13):1375-83.
DOI: 10.1097/01.aids.0000181011.62385.91
Blümer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008; 22(2):227-36.
DOI: 10.1097/QAD.0b013e3282f33557
Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010; 24(2):243-53.
DOI: 10.1097/QAD.0b013e328333ea9e
Bogorodskaya M, Fitch KV, Lu M, Torriani M, Zanni MV, Looby SE, et al. Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. Obesity (Silver Spring). 2020; 28(4):749-755.
DOI: 10.1002/oby.22742
Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017; 4(4):e154-e160.
DOI: 10.1016/S2352-3018(17)30016-4
Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, et al. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. Clin Infect Dis. 2020; 71(9): e471-e477.
DOI: 10.1093/cid/ciaa177
McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, et al. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clin Infect Dis. 2016; 62(7):853-62.
DOI: 10.1093/cid/ciw017
Bhagwat P, Ofotokun I, McComsey GA, Brown TT, Moser C, Sugar CA, et al. Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race. Open Forum Infect Dis. 2018; 5(11): ofy201.
DOI: 10.1093/ofid/ofy201
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 2017; 31(18):2503-2514.
DOI: 10.1097/QAD.0000000000001675
Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, et al. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019; 381(9): 816-826.
DOI: 10.1056/NEJMoa1904340
Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens. J Acquir Immune Defic Syndr. 2017; 76(5):527-531.
DOI: 10.1097/QAI.0000000000001525
Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020; 7(10): e666-e676.
DOI: 10.1016/S2352-3018(20)30241-1
Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020; 71(6):1379-1389.
DOI: 10.1093/cid/ciz999
Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020; 23(4): e25484.
DOI: 10.1002/jia2.25484
Coelho LE, Jenkins CA, Shepherd BE, Pape JW, Mejia Cordero F, Padgett D, et al. Weight gain post-ART in HIV+ Latinos/as differs in the USA, Haiti, and Latin America. Lancet Reg Health Am. 2022; 8:100173.
DOI: 10.1016/j.lana.2021.100173
Bakal DR, Coelho LE, Luz PM, Clark JL, De Boni RB, Cardoso SW, et al. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors. J Antimicrob Chemother. 2018; 73(8):2177-2185.
DOI: 10.1093/jac/dky145
Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, et al. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2021; 73(2):e485-e493.
DOI: 10.1093/cid/ciaa988
Schafer JJ, Sassa KN, O'Connor JR, Shimada A, Keith SW, DeSimone JA. Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide. Open Forum Infect Dis. 2019; 6(10): ofz414.
DOI: 10.1093/ofid/ofz414
Kauppinen KJ, Aho I, Sutinen J. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain. AIDS. 2022; 36(10):1337-1344.
DOI: 10.1097/QAD.0000000000003245
Verburgh ML, Wit FWNM, Boyd A, Reiss P, Van der Valk M; ATHENA national observational cohort. No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain. AIDS. 2023 Oct 1;37(12):1843-1850.
DOI: 10.1097/QAD.0000000000003654
Wohl DA, Koethe JR, Sax PE, McComsey GA, Kuritzkes DR, Moyle G, et al. Antiretrovirals and Weight Change: Weighing the Evidence. Clin Infect Dis. 2024; 12:ciae191.
DOI: 10.1093/cid/ciae191
Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis. 2006; 42(6):836-42.
DOI: 10.1086/500398
Tate T, Willig AL, Willig JH, Raper JL, Moneyham L, Kempf MC, et al. HIV infection and obesity: where did all the wasting go? Antivir Ther. 2012; 17(7):1281-9.
DOI: 10.3851/IMP2348
Kumar S, Samaras K. The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Front Endocrinol (Lausanne). 2018; 9:705.
DOI: 10.3389/fendo.2018.00705
Otake K, Omoto S, Yamamoto T, Okuyama H, Okada H, Okada N,et al. HIV-1 Nef protein in the nucleus influences adipogenesis as well as viral transcription through the peroxisome proliferator-activated receptors. AIDS. 2004; 18(2):189-98.
DOI: 10.1097/00002030-200401230-00007
Agarwal N, Iyer D, Patel SG, Sekhar RV, Phillips TM, Schubert U, et al. HIV-1 Vpr induces adipose dysfunction in vivo through reciprocal effects on PPAR/GR co-regulation. Sci Transl Med. 2013; 5(213):213ra164.
DOI: 10.1126/scitranslmed.3007148
Pérez-Matute P, Pérez-Martínez L, Blanco JR, Oteo JA. Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. Oxid Med Cell Longev. 2013; 2013:493413.
DOI: 10.1155/2013/493413
Gorwood J, Ejlalmanesh T, Bourgeois C, Mantecon M, Rose C, Atlan M,et al. SIV Infection and the HIV Proteins Tat and Nef Induce Senescence in Adipose Tissue and Human Adipose Stem Cells, Resulting in Adipocyte Dysfunction. Cells. 2020a; 9(4):854.
DOI: 10.3390/cells9040854
Bailin SS, Gabriel CL, Fan R, Ye F, Nair S, Terry JG, et al. Relationship of Subcutaneous Adipose Tissue Inflammation-Related Gene Expression With Ectopic Lipid Deposition in Persons With HIV. J Acquir Immune Defic Syndr. 2022; 90(2):175-183.
DOI: 10.1097/QAI.0000000000002926
Gorwood J, Bourgeois C, Pourcher V, Pourcher G, Charlotte F, Mantecon M, et al. The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes. Clin Infect Dis. 2020b; 71(10):e549-e560.
DOI: 10.1093/cid/ciaa259
Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and Weight Gain in Persons with HIV. Curr HIV/AIDS Rep. 2020; 17(2):138-150.
DOI: 10.1007/s11904-020-00483-5
Ngono Ayissi K, Gorwood J, Le Pelletier L, Bourgeois C, Beaupère C, Auclair M, et al. Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes. Cells. 2022; 11(11):1841.
DOI: 10.3390/cells11111841
Ahmed B, Farb MG, Gokce N. Cardiometabolic implications of adipose tissue aging. Obes Rev. 2024; 30:e13806.
DOI: 10.1111/obr.13806
Zhao H, Goetz MB. Complications of HIV infection in an ageing population: challenges in managing older patients on long-term combination antiretroviral therapy. J Antimicrob Chemother. 2011; 66(6):1210-4.
DOI: 10.1093/jac/dkr058
Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and Weight Gain in Persons with HIV. Curr HIV/AIDS Rep. 2020; 17(2):138-150.
DOI: 10.1007/s11904-020-00483-5
Kim DJ, Westfall AO, Chamot E, Willig AL, Mugavero MJ, Ritchie C, et al. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr. 2012; 61(5):600–5. 9.
DOI: 10.1097/QAI.0b013e31827303d5
Sattler FR, He J, Letendre S, Wilson C, Sanders C, Heaton R, et al. Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation. J Acquir Immune Defic Syndr. 2015; 68(3):281–8.
DOI: 10.1097/QAI.0000000000000458
Milic J, Calza S, Cantergiani S, Albertini M, Gallerani A, Menozzi M, et al. Sarcopenic Obesity Phenotypes in Patients With HIV: Implications for Cardiovascular Prevention and Rehabilitation. Can J Cardiol. 2023; 39(11S): S359-S367.
DOI: 10.1016/j.cjca.2023.08.027
Capeau J, Lagathu C, Ngono Ayissi K, Fève B, Béréziat V. HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals. Ann Endocrinol (Paris). 2024; 85(3):255-258.
DOI: 10.1016/j.ando.2024.05.005
Patel YS, Doshi AD, Levesque AE, Lindor S, Moranville RD, Okere SC, et al. Weight Gain in People with HIV: The Role of Demographics, Antiretroviral Therapy, and Lifestyle Factors on Weight. AIDS Res Hum Retroviruses. 2023; 39(12):652-661.
DOI: 10.1089/aid.2023.0008
Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Toribio M, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024; 38(12):1758-1764.
DOI: 10.1097/QAD.0000000000003965
Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014; 312(4):380-9.
DOI: 10.1001/jama.2014.8334
Eckard AR, Wu Q, Sattar A, Ansari-Gilani K, Labbato D, Foster T, et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. Lancet Diabetes Endocrinol. 2024; 12(8):523-534.
DOI: 10.1016/S2213-8587(24)00150-5
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021; 385(6):503-515.
DOI: 10.1056/NEJMoa2107519
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023; 389(6):514-526.
DOI: 10.1056/NEJMoa2301972
UNAIDS. Understanding measures of progress towards the 95–95–95 HIV testing, treatment and viral suppression targets. 2024. Updated March 11, 2024. Available from: https://www.unaids.org/sites/default/files/media_asset/progress-towards-95-95-95_es.pdf [Accessed on August 11, 2024].
Bavaro DF, Laghetti P, Poliseno M, De Gennaro N, Di Gennaro F, Saracino A. A Step Closer to the "Fourth 90": A Practical Narrative Review of Diagnosis and Management of Nutritional Issues of People Living with HIV. Diagnostics (Basel). 2021; 11(11):2047.
DOI: 10.3390/diagnostics11112047